Nobukazu Fujimoto

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

Arnaud Scherpereel, Anna K. Nowak, Nobukazu Fujimoto et al. · The Lancet · 2021 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +14

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743

Solange Peters, Arnaud Scherpereel, Robin Cornelissen et al. · Annals of Oncology · 2022 · 263 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Identification of Epigenetic Aberrant Promoter Methylation in Serum DNA Is Useful for Early Detection of Lung Cancer

Keiichi Fujiwara, Nobukazu Fujimoto, Masahiro Tabata et al. · Clinical Cancer Research · 2005 · 202 citations · Full text

Medicine, Molecular Biology, Oncology +17

High Expression of Ligands for Chemokine Receptor CXCR2 in Alveolar Epithelial Neoplasia Induced by Oncogenic Kras

Marie Wislez, Nobukazu Fujimoto, Julie Izzo et al. · Cancer Research · 2006 · 162 citations

Life Sciences, Cancer Biology, Oncology +17

High Expression of ErbB Family Members and Their Ligands in Lung Adenocarcinomas That Are Sensitive to Inhibition of Epidermal Growth Factor Receptor

Nobukazu Fujimoto, Marie Wislez, Jie Zhang et al. · Cancer Research · 2005 · 144 citations · Full text

Medicine, Molecular Biology, Oncology +17